Women back idea of more breast screens for those at high risk of cancer

February 20, 2015

Most women (85 per cent) would back the idea of more frequent breast screening if they are at higher genetic risk of developing breast cancer, according to research* published today by The Breast.

Fewer women (60 per cent) would be happy to be screened less often if they were found to be at lower risk.**

More than 940 women from across the UK were asked for their views on the possibility of tailoring breast screening to people's genetic risk in a study funded by Cancer Research UK and The Eve Appeal. Two-thirds (66 per cent) supported the idea of adjusting the frequency of screening on the basis of risk.

The NHS breast screening programme offers routine mammograms based on age, rather than genetic risk. All women between 50 and 70 are invited for screening every three years, and women over 70 can request screening if they wish, because older women are at increased risk of the disease. Women with a strong family history of breast cancer may be offered a different pattern of screening.

Breast screening can help detect cancers early, when treatment is more likely to be effective, and is estimated to save around 1,300 lives from breast cancer in the UK each year.

But as well as picking up cancers that need treating, screening can also detect very slow-growing cancers that would not have been picked up without screening. This means some women are treated unnecessarily for a cancer that would not have caused any problem during their lifetimes.

Dr Susanne Meisel, research psychologist at UCL (University College London), said: "Looking at whether genetic risk could be used to tailor and improve the breast screening programme is still at an early stage, but it's useful to find out now what the public might think about this idea. Our study showed that, overall, women seem to support it.

"It's interesting there was less support for the idea of less frequent screening for people at lower risk of cancer. This could be because many women tend to see screening as beneficial or feel they have a right to screening, or some women might take a 'better safe than sorry' approach to cancer screening which may make them more accepting of potential harm from it."

Women who took part in the study were asked five questions to assess what they believed their risk of developing breast cancer was, and their attitude to genetic testing and using genetic risk to vary screening frequency. Limited information was provided on how a modified screening programme might work, and no information was given on the current screening programme.

Athena Lamnisos, CEO of The Eve Appeal, said: "Women at increased risk of cancer deserve more than the one-size fits all approach. This study shows that women were positive about the idea of adjusting the frequency of mammography screening in line with personal genetic risk. It also shows how critical it is to develop effective communication materials - both for women at high risk and those at lower genetic risk."

Jessica Kirby, senior health information manager at Cancer Research UK, said: "Breast screening saves lives, but it also has risks. One suggestion to try to maximise the benefit and reduce the risk is to tailor screening more effectively to people's risk of breast cancer, but more research is needed to show whether this approach will be effective or possible.

"This interesting study suggests that women are generally positive about the idea of tailoring screening, but in the meantime, it's critical that women are offered proper information about the benefits and risks of screening, and supported to make an informed decision."
-end-
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.

Notes to editor:

*Susanne F Meisel et al - 'Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK'.

The data are drawn from the health behaviour aspect of PROMISE 2016. Researchers are based at the Health Behaviour Research Centre, UCL; Department of Applied Health Research, UCL; and the Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, UCL.

** 942 women were asked the following five questions and answered by choosing one of a number of set responses:

It is possible that breast screening frequency could be varied depending on whether a woman is at higher or lower genetic risk of breast cancer. What do you think of the idea of varying the frequency of breast screening?

Would you personally be happy to have your breast screening more often if you were found to be at higher genetic risk of breast cancer?

Would you personally be happy to have your breast screening less often if you were found to be at lower genetic risk of breast cancer?

Based on what you know, do you think genetic testing will do more good than harm, or more harm than good?

Compared with other women of your age, what do you think are your chances of getting breast cancer?

65.8 per cent of the women supported the idea of varying screening frequency on the basis of genetic risk; 85.4 per cent were willing to have more frequent breast screening if they were found to be at higher risk; 58.8 per cent were willing to have less frequent screening if at lower risk.

The work was undertaken within "PROMISE 2016" a 5 year research programme led by Principal Investigator Prof Ian Jacobs focused on developing novel risk prediction models for use in ovarian cancer screening. PROMISE takes a personalised screening approach by predicting a woman's risk of ovarian cancer using clinical, epidemiological, proteomic and genetic data, and stratifying the subsequent information, support and risk management options depending on the woman's level of risk. Genetic data will include testing the high penetrance genes associated with hereditary breast and ovarian cancer, BRCA1 and BRCA2, as well lower penetrance genes associated with ovarian cancer susceptibility. The work has the potential to streamline cancer screening and reduce overdiagnosis and overtreatment.

About The Eve Appeal

The Eve Appeal is the only UK national charity raising awareness and funding research in the five gynaecological cancers - ovarian, womb, cervical, vaginal and vulval.

It was set up to save women's lives by funding groundbreaking research focused on developing effective methods of risk prediction, earlier detection and developing screening for these women-only cancers.

The charity's core research team, the Department of Women's Cancer at University College London (UCL), and The Eve Appeal has played a crucial role in providing seed funding, core infrastructure funding and project funding to a broad range of it's programmes, including PROMISE2016 which this research project fits within.

Our vision is simple: A future where fewer women develop and more women survive gynaecological cancers.

For further information about The Eve Appeal's research and public awareness raising work or to find out how to support the charity, please call 0207 605 0100 or visit http://www.eveappeal.org.uk. Follow us on Twitter @TheEveAppeal and Facebook.

For more information about our research programme in risk prediction, prevention and early detection of women's cancers, visit http://www.eveappeal.org.uk/news-info/research-review-(2009-2014)/

About Cancer Research UK

Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.

Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.

Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.

Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.

Today, 2 in 4 people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.

Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.

Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.

For more information on the Cross Cancer Out campaign, and ways the public can get involved, visit cruk.org/crosscancerout and join the conversation on twitter using #CrossCancerOut.

Cancer Research UK

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.